Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) SEC filings page on Stock Titan provides structured access to the company’s U.S. regulatory disclosures. As a British Columbia–incorporated, globally active pharmaceutical issuer with common shares listed on the New York Stock Exchange and Toronto Stock Exchange, Bausch Health files a variety of documents with the U.S. Securities and Exchange Commission under Commission File Number 001-14956.
Investors can review current reports on Form 8-K that describe material events such as exchange offers for senior secured notes, amendments to credit agreements at Bausch Health and Bausch + Lomb, completion of acquisitions like DURECT Corporation, quarterly financial results, shareholder meeting outcomes and other significant corporate actions. These filings also summarize key terms of new 10.00% Senior Secured Notes due 2032, related indentures and collateral arrangements, including pledges of Bausch + Lomb shares.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically provide more comprehensive detail on Bausch Health’s segments—Salix, International, Solta Medical, Diversified Products and Bausch + Lomb—along with risk factors, management’s discussion and analysis and notes on non-GAAP metrics the company uses, such as organic revenue growth and adjusted EBITDA. Proxy materials and governance-related filings give additional insight into matters like the Amended and Restated Shareholder Rights Plan Agreement and shareholder voting results.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping users understand changes in debt structure, covenant terms, segment performance and strategic transactions without reading every page. Real-time updates from EDGAR, along with visibility into items such as potential insider transaction reports on Form 4, allow users to monitor how Bausch Health reports its financial condition, capital structure decisions and corporate governance developments over time.
Bausch Health Companies Inc. director Sandra Leung received an equity compensation award in the form of Restricted Share Units for her board service for the quarter ending March 31, 2026. She acquired 5,946 common shares at a deemed price of $5.40 per share, bringing her direct holdings to 44,354 common shares.
Bausch Health Companies Inc. director John Paulson reported an equity compensation grant rather than an open-market trade. He acquired 11,574 common share equivalents at $5.40 per share as Restricted Share Units issued in lieu of cash fees for his board service for the quarter ending March 31, 2026.
After this award, he holds 371,694 common shares directly and has an additional 73,255,869 shares reported as indirectly owned by managed funds. A footnote states these securities are directly owned by the funds, and Paulson disclaims beneficial ownership except to the extent of any pecuniary interest.
Bausch Health Companies Inc. director Amy B. Wechsler received an equity-based compensation award for Board service. She acquired 1,273 Restricted Share Units issued in lieu of cash compensation for the quarter ending March 31, 2026, each representing a contingent right to receive one common share. Following this grant, she directly holds 267,714 common shares, including the awarded units.
Bausch Health Companies Inc. executive vice president and CFO Jean-Jacques Charhon reported a tax-related share disposition. On the vesting of Restricted Share Units, 49,060 common shares at $5.93 per share were withheld to cover tax obligations, a non-market transaction. After this withholding, Charhon directly holds 706,478 common shares.
Bausch Health Companies Inc. EVP and General Counsel Seana Carson reported several equity transactions in the company’s common shares. She sold 6,856 shares on March 2, 2026 at $5.78 per share and 4,420 shares on March 3, 2026 at $5.77 per share in open-market sales under a pre-arranged Rule 10b5-1 trading plan. The filing also shows share dispositions used to cover tax withholding on vesting of restricted share units, and a cash settlement of 137,922 previously earned performance share unit awards under the company’s 2014 Omnibus Incentive Plan. After the most recent sale, Carson directly holds 616,761 common shares of Bausch Health.
Bausch Health Companies Inc. director and CEO Thomas Appio reported equity award-related transactions in common shares, no par value. On February 27, 2026 and March 2, 2026, the company withheld 83,093 and 83,705 shares, respectively, to satisfy tax withholding obligations upon vesting of restricted share units.
The filing also records an "other" transaction for 1,137,862 performance share unit awards that will be settled in cash rather than company stock, as approved by the board committee and previously disclosed. Following these transactions, Appio directly held 3,453,236 common shares on March 2, 2026.
BHC reported a Form 144 notice for proposed sales of common stock by an insider. The filing lists two sale transactions by Seana Carson: 8,388 shares on 02/27/2026 for $49,908.60 and 6,856 shares on 03/02/2026 for $39,627.68.
The filing also shows 4,420 shares tied to restricted stock vesting on 03/02/2026 labeled as Issuer / Compensation. The record lists a brokerage account at Fidelity Brokerage Services LLC.
Bausch Health Companies Inc. updated how certain 2023 performance share units (PSUs) for two senior executives will be paid out. These PSUs were granted in March 2023, tied to a three-year performance period, and are scheduled to vest on March 3, 2026.
For CEO Thomas Appio, the award agreement covering 1,137,862 2023 PSUs was amended so that, at vesting, the earned PSUs will be settled solely in cash equal to the market price of Bausch Health common shares, using the closing price on the vesting date. For executive Lisa Carson, an agreement provides that she will irrevocably surrender her 137,922 2023 PSUs in exchange for a cash amount based on the same market price definition.
The company notes that full details of the Appio and Carson agreements will be included as exhibits to its Form 10‑Q for the quarter ending March 31, 2026.
BHC reported a Form 144 notice indicating a proposed sale of 6,856 common shares through Fidelity Brokerage Services LLC on 03/02/2026 for exchange listing NYSE. The filing also shows a recent disposition of 8,388 common shares on 02/27/2026 for $49,908.60.
LEE STEVEN HYOSIG reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. reported that senior vice president, controller and chief accounting officer Steven Hyosig Lee received an equity grant in the form of restricted share units. He was awarded 45,868 common share RSUs at no purchase price, which will vest in three equal annual installments.
These units vest one-third on each of the first three anniversaries of the grant date, conditional on his continued service. Once vested, each RSU will be settled in one common share of Bausch Health. Following this grant, his directly held common shares total 73,239.